Jane Street Group, LLC Ultragenyx Pharmaceutical Inc. Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

A detailed history of Jane Street Group, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 131,441 shares of RARE stock, worth $5.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
131,441
Previous 185,061 28.97%
Holding current value
$5.97 Million
Previous $7.61 Million 4.01%
% of portfolio
0.0%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$40.21 - $59.36 $2.16 Million - $3.18 Million
-53,620 Reduced 28.97%
131,441 $7.3 Million
Q2 2024

Aug 14, 2024
BUY
$37.42 - $51.61 $4.48 Million - $6.17 Million
119,623 Added 182.8%
185,061 $7.61 Million
Q1 2024

May 15, 2024
SELL
$43.02 - $53.69 $2.38 Million - $2.97 Million
-55,277 Reduced 45.79%
65,438 $3.06 Million
Q4 2023

Feb 14, 2024
BUY
$31.73 - $49.19 $2.89 Million - $4.48 Million
91,065 Added 307.13%
120,715 $5.77 Million
Q3 2023

Nov 14, 2023
SELL
$34.92 - $46.66 $1.68 Million - $2.24 Million
-47,977 Reduced 61.8%
29,650 $1.06 Million
Q2 2023

Aug 14, 2023
BUY
$37.35 - $52.15 $1.82 Million - $2.55 Million
48,854 Added 169.79%
77,627 $3.58 Million
Q1 2023

May 15, 2023
SELL
$36.99 - $48.71 $77,309 - $101,803
-2,090 Reduced 6.77%
28,773 $1.15 Million
Q4 2022

Feb 14, 2023
SELL
$33.72 - $46.33 $139,499 - $191,667
-4,137 Reduced 11.82%
30,863 $1.43 Million
Q3 2022

Nov 14, 2022
BUY
$39.96 - $66.14 $953,485 - $1.58 Million
23,861 Added 214.21%
35,000 $1.45 Million
Q2 2022

Aug 16, 2022
BUY
$45.8 - $85.4 $377,758 - $704,379
8,248 Added 285.3%
11,139 $664,000
Q1 2022

May 17, 2022
SELL
$62.2 - $84.4 $1.56 Million - $2.12 Million
-25,117 Reduced 89.68%
2,891 $210,000
Q4 2021

Feb 15, 2022
SELL
$73.71 - $87.86 $250,098 - $298,108
-3,393 Reduced 10.81%
28,008 $2.36 Million
Q3 2021

Nov 16, 2021
SELL
$77.92 - $102.4 $2.76 Million - $3.63 Million
-35,422 Reduced 53.01%
31,401 $2.83 Million
Q2 2021

Aug 16, 2021
BUY
$92.19 - $115.71 $5.65 Million - $7.09 Million
61,250 Added 1099.05%
66,823 $6.37 Million
Q1 2021

May 18, 2021
SELL
$106.9 - $167.73 $2.97 Million - $4.66 Million
-27,791 Reduced 83.3%
5,573 $635,000
Q4 2020

Feb 17, 2021
BUY
$84.4 - $177.39 $1.05 Million - $2.21 Million
12,467 Added 59.66%
33,364 $4.62 Million
Q3 2020

Nov 17, 2020
SELL
$72.98 - $90.0 $101,515 - $125,190
-1,391 Reduced 6.24%
20,897 $1.72 Million
Q2 2020

Aug 17, 2020
BUY
$46.91 - $78.22 $1.05 Million - $1.74 Million
22,288 New
22,288 $1.74 Million
Q1 2020

May 15, 2020
SELL
$33.8 - $62.9 $664,203 - $1.24 Million
-19,651 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$36.08 - $45.83 $334,317 - $424,660
9,266 Added 89.22%
19,651 $839,000
Q3 2019

Nov 14, 2019
BUY
$42.5 - $63.11 $441,362 - $655,397
10,385 New
10,385 $444,000
Q4 2018

Feb 15, 2019
SELL
$38.89 - $77.3 $995,661 - $1.98 Million
-25,602 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$71.81 - $90.15 $1.84 Million - $2.31 Million
25,602 New
25,602 $1.95 Million
Q2 2018

Aug 15, 2018
SELL
$48.54 - $85.31 $322,888 - $567,482
-6,652 Closed
0 $0
Q1 2018

May 15, 2018
SELL
$44.33 - $58.52 $96,151 - $126,929
-2,169 Reduced 24.59%
6,652 $339,000
Q4 2017

Feb 15, 2018
BUY
$43.54 - $57.32 $79,591 - $104,780
1,828 Added 26.14%
8,821 $409,000
Q3 2017

Nov 14, 2017
BUY
$49.79 - $66.32 $348,181 - $463,775
6,993
6,993 $372,000

Others Institutions Holding RARE

# of Institutions
326
Shares Held
85.7M
Call Options Held
520K
Put Options Held
406K
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.18B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email